Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 dose-ranging trial in diabetic kidney disease
2020-002929-28Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avenciguat in diabetic glomerulosclerosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in log transformed urine albumin creatinine ratio in 10-hour urine at 20 weeks. Started Feb 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2020-002929-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002929-28.